News &amp; Updates

Tacrolimus outclasses cyclosporine after liver transplantation for PSC

19 Jan 2024 by

Tacrolimus appears to be more effective than cyclosporine in improving patient and graft survival after liver transplantation (LT) for primary sclerosing cholangitis (PSC), results of a study have shown.

Tacrolimus outclasses cyclosporine after liver transplantation for PSC

Linaclotide works well for functional constipation in children

The guanylate cyclase C agonist linaclotide helps increase the frequency of bowel movements in children with functional constipation, according to data from a phase III trial.

Linaclotide works well for functional constipation in children

Mirtazapine ups calorie consumption in NSCLC patients with anorexia

18 Jan 2024 by

In advanced nonsmall cell lung cancer (NSCLC) patients with anorexia, treatment with mirtazapine leads to a substantial increase in energy intake despite having no effect on appetite, as shown in a study.

Mirtazapine ups calorie consumption in NSCLC patients with anorexia

Original New Drug Application Approvals by US FDA (01-15 January 2024)

New drug applications approved by US FDA as of 01-15 January 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 January 2024)

Adjuvant chemo confers no survival advantage following biliary tract cancer resection

In older patients with resected biliary tract cancer, adjuvant chemotherapy does not appear to yield significant survival gains when compared with observation, according to a study.

Adjuvant chemo confers no survival advantage following biliary tract cancer resection

Rituximab resolves complications in anti-MDA5–positive JDM

17 Jan 2024

Treatment with rituximab (RTX) in children with juvenile dermatomyositis (JDM) and antibodies to antimelanoma differentiation-associated gene 5 (anti-MDA5) results in clinical improvements in interstitial lung disease (ILD) as well as in cutaneous manifestation and musculoskeletal disease activity, according to a study.

Rituximab resolves complications in anti-MDA5–positive JDM

17 Jan 2024

Ganaxolone delivers sustained reductions in CDD-related seizures

Treatment with ganaxolone in paediatric patients with cyclin-dependent kinase-like 5 deficiency disorder (CDD) leads to reductions in major motor seizure frequency (MMSF) over 2 years, according to data from the open-label extension phase of the Marigold trial.

Ganaxolone delivers sustained reductions in CDD-related seizures

GLP-1RA users face no elevated risk of pancreatic cancer

16 Jan 2024 by

Among individuals with type 2 diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) does not contribute to increased pancreatic cancer risk, according to a study.

GLP-1RA users face no elevated risk of pancreatic cancer

16 Jan 2024

DOAC vs VKA: Which agent must be used after TMVR?

Patients who received direct oral anticoagulants (DOACs) following transcatheter mitral valve replacement (TMVR) seem to have a lower risk of bleeding complications and shorter length of hospital stay, with no significant increase in the risk of thrombotic events, than those treated with vitamin K antagonists (VKAs), a study has shown.

DOAC vs VKA: Which agent must be used after TMVR?